2. Signaling Pathways
  3. Immunology/Inflammation
  4. P-selectin

P-selectin

CD62

P-selectin (CD62) is a type 1 transmembrane protein encoded by the selectin-P (SELP) gene in humans. It is produced in megakaryocytes and endothelial cells and is packaged in platelet α-granules and endothelial Weibel-Palade bodies. Upon stimulation, P-selectin rapidly mobilizes to the cell surface and is then externalized. Just as rapidly, P-selectin can be re-internalized and destroyed or recycled. The major ligand for P-selectin is P-selectin glycoprotein ligand-1 (PSGL-1), which is present on most leukocytes. P-selectin also binds platelet glycoprotein (Gp)1b, promoting leukocyte and platelet rolling and adhesion. P-selectin also triggers the release of procoagulant microparticles and increases tissue factor expression on monocytes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-106139
    Bimosiamose
    		Inhibitor ≥99.0%
    Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose has anti-inflammatory effects.
    Bimosiamose
  • HY-103358
    KF38789
    		Inhibitor 99.56%
    KF38789 is a selective inhibitor of P-selectin-PSGL-1 binding. KF38789 inhibits the binding of U937 cells to immobilized P-selectin immunoglobulin G chimeric protein (P-selectin-Ig) with an IC50 value of 1.97 μM.
    KF38789
  • HY-15526
    PSI-697
    		Inhibitor 99.79%
    PSI-697 is an oral P-selectin inhibitor with an IC50 of 125 μM.
    PSI-697
  • HY-P9987
    Crizanlizumab
    		Inhibitor
    Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
    Crizanlizumab
  • HY-P99263
    Inclacumab
    		Inhibitor 99.80%
    Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion.
    Inclacumab
  • HY-P11798
    P-Selectin binding peptide
    		Ligand
    P‑Selectin binding peptide is a short peptide that specifically targets P‑selectin. P‑Selectin binding peptide binds with high affinity to P‑selectin, which is highly expressed on activated platelets, inflamed endothelium, and in the tumor microenvironment. P‑Selectin binding peptide is used for precise targeted delivery and intervention in inflammation, thrombosis, and tumors.
    P-Selectin binding peptide
  • HY-P6442
    Chemerin15
    		99.65%
    Chemerin15 is an anti-inflammatory peptide derived from Chemerin. Chemerin15 binds to ChemR23. Chemerin15 inhibits TNFα-induced activation of Syk, ERK and Src kinases. Chemerin15 increases the expression of p-p38 mRNA and protein. Chemerin15 mediates phagocytosis, resolution of inflammation, CD62L shedding and downregulation of PSGL-1 expression in macrophages and microglia. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury via ChemR23. Chemerin15 enhances microglial phagocytosis, thereby alleviating cerebral ischemia-reperfusion injury.
    Chemerin15
  • HY-P99443
    Aselizumab
    		Inhibitor 99.76%
    Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma.
    Aselizumab
  • HY-132828
    Odatroltide
    		Inhibitor
    Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities.
    Odatroltide
  • HY-122655
    HMCEF
    		Inhibitor
    HMCEF is an orally active P-selectin inhibitor and inhibits P-selectin expression. HMCEF blocks the interaction between P-selectin and natural ligands, such as PSGL-1. HMCEF inhibits thrombosis and inflammation in mice.
    HMCEF
  • HY-146332
    Collagen-IN-1
    		Inhibitor
    Collagen-IN-1 (compound 3), an ortho-carbonyl hydroquinone derivative, is a selective inhibitor on collagen. Collagen-IN-1 inhibits agonist-induced platelet aggregation in a non-competitive manner with an IC50 value of 1.77 μM. Collagen-IN-1 reduces the expression of P-selectin, activation of glycoprotein IIb/IIIa, and release of adenosine triphosphate and CD63 from platelet. Collagen-IN-1 has the potential for platelet-related thrombosis diseases research.
    Collagen-IN-1
  • HY-P99553
    Torapsel
    		Inhibitor
    Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein with immunoglobiln. Torapsel can be used to research the prevention of ischemia reperfusion injury.
    Torapsel
  • HY-106428
    Icrocaptide
    		Inhibitor
    Icrocaptide (ITF1697) is a stable Lys-Pro-containing peptide that inhibits the intracellular Ca2+-dependent fusion of Weibel-Palade bodies with the plasma membrane. Icrocaptide exerts its activity at the early stages of endothelial activation and inhibits P-selectin and von Willebrand factor secretion. Icrocaptide can be used for the study of a variety of microvascular disorders.
    Icrocaptide
  • HY-P9987A
    Crizanlizumab (anti-P-selectin)
    		Inhibitor
    Crizanlizumab (anti-P-selectin) is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
    Crizanlizumab (anti-P-selectin)
  • HY-106139A
    Bimosiamose disodium
    		Inhibitor
    Bimosiamose disodium (TBC-1269Z) is a nonoligosaccharide pan-selectin inhibitor with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose disodium has anti-inflammatory effects.
    Bimosiamose disodium
  • HY-177800
    ARC5690 sodium
    		Inhibitor
    ARC5690 sodium is an anti-mouse P-selectin aptamer. ARC5690 bound to recombinant mouse P-selectin with a KD of approximately 15pM in vitro. ARC5690 showed a significant anti-inflammatory effect
    ARC5690 sodium
  • HY-119158
    VU0652925
    		Inhibitor
    VU0652925, an analog of BMS986120, is a PAR4 antagonist, with IC50 values of 43 pM and 39.2 pM for PAC1 and P-selectin, respectively. VU0652925 is able to suppress GPIIbIIIa activation.
    VU0652925
  • HY-106139R
    Bimosiamose (Standard)
    		Inhibitor
    Bimosiamose (Standard) is the analytical standard of Bimosiamose. This product is intended for research and analytical applications. Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose has anti-inflammatory effects.
    Bimosiamose (Standard)
Cat. No. Product Name / Synonyms Application Reactivity